ReviewTherapeutic advances in drug safety2018
Medication use and potentially inappropriate prescribing in older adults with intellectual disabilities: a neglected area of research.
Review in Therapeutic advances in drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- Research Patterns in the Treatment of Adults With Problem Behavior and Intellectual and Developmental Disabilities: A Quantitative Systematic Review.Behavior modification · 2026Pooled it
- Impact of nurse-led home visits on medication management and use of medical screenings for adults with intellectual disabilities: a randomised-controlled trial.BMC nursing · 2026Article
- Structured Medication Review and Shared Decision-Making in Patients with Mild Intellectual Disabilities Who Use Psychotropic Medication.Pharmacy (Basel, Switzerland) · 2026Article
- A protocol for application of OPTIMA-ID to identify potentially inappropriate prescribing in a cohort of older adults with intellectual disability.HRB open research · 2026Article
- A Rapid Mapping Review of Medication Burden in Adults with an Intellectual Disability: What We Know and What We Do Not Know.Drug, healthcare and patient safety · 2026Review
- Ten-Year Outcomes of Anticholinergic Use Among Older Adults With Intellectual Disability: Findings From the Intellectual Disability Supplement to the Irish Longitudinal Study on Ageing (IDS-TILDA).Journal of intellectual disability research : JIDR · 2025Article
- Developing and testing of an assessment tool for appropriate psychotropic drug prescribing in people with intellectual disabilities.Therapeutic advances in drug safety · 2025Article
- Exploring Connections Between Living Situations and Antipsychotic Prescribing Practices for People With Intellectual Disabilities.Psychiatric research and clinical practice · 2025Article
- Subcutaneous electroencephalography monitoring for people with epilepsy and intellectual disability: co-production workshops.BJPsych open · 2024Article
- Intellectual disability nurses' challenges in medication management in primary health care: A qualitative study.Journal of intellectual disabilities : JOID · 2024Article
- Challenges and responsibilities in the medication management process in 24/7 group housing services for adults with intellectual disability: Interviews with nurses.Journal of intellectual disabilities : JOID · 2024Article
- Adverse events and contradictory effects of benzodiazepine in a case with intellectual disability and challenging behaviour.Journal of intellectual disabilities : JOID · 2024Article
- Efficacy of clozapine versus standard treatment in adult individuals with intellectual disability and treatment-resistant psychosis (CLOZAID): study protocol of a multicenter randomized clinical trial.Frontiers in psychiatry · 2024Article
- 'Stakeholders are almost always resistant': Australian behaviour support practitioners' perceptions of the barriers and enablers to reducing restrictive practices.International journal of developmental disabilities · 2023Article
- Aligning quality of life and guidelines for off-label psychotropic drugs in adults with intellectual disabilities and challenging behaviour.International journal of developmental disabilities · 2023Article
- Ageing people with intellectual disabilities and the association between frailty factors and social care: A Swedish national register study.Journal of intellectual disabilities : JOID · 2022Article
- Adverse Effects in Patients with Intellectual and Developmental Disabilities Hospitalized at the University Clinical Hospital.Journal of personalized medicine · 2022Article
- Rating scales to measure adverse effects of medications in people with intellectual disability: a scoping review.European journal of clinical pharmacology · 2022Article
- Psychotropic drugs intake in people aging with intellectual disability: Prevalence and predictors.Journal of applied research in intellectual disabilities : JARID · 2022Article
- Community-Based Support and Social Services and Their Association with Frailty Factors in Older People with Intellectual Disability and Affective and Anxiety Disorders: A Swedish National Population-Based Register Study.Community mental health journal · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is known that for all adults, prevalence of potentially inappropriate prescribing (PIP) and polypharmacy increases with advancing age and morbidity. This has been associated with adverse drug reactions and poor outcomes. As a result, screening tools have been developed to identify PIP and to improve prescribing and health outcomes. A growing body of evidence supports the fact that there are even greater concerns among older adults with intellectual disability (ID) who are living longer than before but still have premature mortality and poorer health outcomes compared with the general population. They have different patterns of multimorbidity, with higher rates of epilepsy and mental health conditions. Polypharmacy is prevalent and some prescribing practices may be inappropriate. High exposure to anticholinergic and sedative medicines has additional adverse effects on quality of life. There may also be underutilization of clinically needed therapies. There has been substantial controversy internationally relating to extensive use of psychotropic medicines, particularly off-label use for challenging behaviours. Despite the mounting evidence and concerns about the impact of PIP on quality of life, health and safety for people with ID, appropriate methods to measure PIP are lacking, which represents an important gap in the research literature. Differences in morbidity and medicines use patterns in this population mean instruments used to identify inappropriate medicines in the older population are not suitable. In this perspective article we outline the specific health and medicinal needs for people with ID, the prevalence of polypharmacy and presentation of chronic health conditions in older adults with ID. We provide an overview of the psychotropic medicine classes most frequently used in people with ID which carry substantial risk. We highlight studies to date that have attempted to assess PIP and present research priorities to improve prescribing, health outcomes and quality of life for people with ID.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.